Lilly stock hits record after Mounjaro, Zepbound drive 48% revenue jump
Second-quarter non-GAAP EPS of $8.38 beat estimates by 31%, prompting Lilly to lift full-year revenue guidance to $85-87 billion.
The wire
- 01Eli Lilly reported Q2 revenue of $22.97 billion, up 48% year over year, with Mounjaro at $9.94 billion and Zepbound at $4.93 billion; shares touched an intraday record $1,292.65 on August 19.
- 02Incretin demand is still compounding for the market leader, shaping supply, pricing and payer negotiations that compounders and telehealth operators must plan around.
- 03Guidance was raised to $35.50-$36.50 EPS, but the figures come from an aggregator citing Reuters, and analyst price targets range widely from roughly $1,299 to $1,600.
From the source
Read at eciks.orgEli Lilly stock hits record high of $1,292.65 on strong earnings momentum
Eli Lilly stock touched an intraday record high of $1,292.65 on August 19, extending a surge driven by the company’s strong second-quarter earnings beat and raised full-year guidance. The pharmaceutical giant delivered non-GAAP earnings per share of $8.38, crushing analyst estimates of $6.40 by 31%, as revenue climbed 48% year-over-year to $22.97 billion.